• 1
    Klempner MS. Controlled trials of antibiotic treatment in patients with post-treatment chronic Lyme disease. Vector Borne Zoonotic Dis 2002; 2: 25563.
  • 2
    Marques AR, Stock F, Gill V. Evaluation of a new culture medium for Borrelia burgdorferi. J Clin Microbiol 2000; 38: 423941.
  • 3
    Yrjanainen H, Hytonen J, Song XY, Oksi J, Hartiala K, Viljanen MK. Anti-tumor necrosis factor-α treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice. J Infect Dis 2007; 195: 148996.
  • 4
    Sigal LH. Summary of the first 100 patients seen at a Lyme disease referral center. Am J Med 1990; 88: 57781.
  • 5
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990; 33: 16072.
  • 6
    Reid MC, Schoen RT, Evans J, Rosenberg JC, Horwitz RI. The consequences of overdiagnosis and overtreatment of Lyme disease: an observational study. Ann Intern Med 1998; 128: 35462.
  • 7
    Steere AC, Taylor E, McHugh GL, Logigian EL. The overdiagnosis of Lyme disease. JAMA 1993; 269: 18126.
  • 8
    Cameron D, Gaito A, Harris N, Bach G, Bellovin S, Bock K, et al, for the ILADS Working Group. Evidence-based guidelines for the management of Lyme disease. Expert Rev Anti Infect Ther 2004; 2: S113.
  • 9
    Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, et al. Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 2001; 345: 8592.
  • 10
    Sigal LH. The Lyme disease controversy: social and financial costs of misdiagnosis and mismanagement. Arch Intern Med 1996; 156: 1493500.
  • 11
    Sigal LH, Hassett AL. Contributions of societal and geographical environments to “chronic Lyme disease”: the psychopathogenesis and aporology of a new “medically unexplained symptoms” syndrome. Environ Health Perspect 2002; 110 Suppl 4: 60711.
  • 12
    Sigal LH, Hassett AL. “What's in a name? That which we call a rose by any other name would smell as sweet.” Int J Epidemiol 2005; 34: 134547.
  • 13
    Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, Klempner MS, et al. The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43: 1089134.
  • 14
    Feder HM Jr, Johnson BJ, O'Connell S, Shapiro ED, Steere AC, Wormser GP, et al. A critical appraisal of “chronic Lyme disease” [published erratum appears in N Engl J Med 2008;358:1084]. N Engl J Med 2007; 357: 142230.
  • 15
    Hassett AL, Cone JD, Patella SJ, Sigal LH. The role of catastrophizing in the pain and depression of women with fibromyalgia syndrome. Arthritis Rheum 2000; 43: 2493500.
  • 16
    Edwards RR, Bingham CO 3rd, Bathon J, Haythornthwaite JA. Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases [review]. Arthritis Rheum 2006; 55: 32532.
  • 17
    Connelly M, Keefe FJ, Affleck G, Lumley MA, Anderson T, Waters S. Effects of day-to-day affect regulation on the pain experience of patients with rheumatoid arthritis. Pain 2007; 131: 16270.
  • 18
    Zautra A, Smith B, Affleck G, Tennen H. Examination of chronic pain and affect relationships: applications of a dynamic model of affect. J Consult Clin Psychol 2001; 69: 78695.
  • 19
    Wharton M, Chorba TL, Vogt RL, Morse DL, Buehler JW. Case definitions for public health surveillance. MMWR Recomm Rep 1990; 39: 143.
  • 20
    Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, Steere AC, et al, for The Infectious Diseases Society of America. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis 2000; 31 Suppl 1: 114.
  • 21
    American Psychiatric Association. Diagnostic and statistical manual of mental disorders: text revision (DSM-IV-TR). 4th ed. Washington, DC: American Psychiatric Press; 2000.
  • 22
    Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. JAMA 1999; 282: 173744.
  • 23
    First MB, Gibbon M, Spitzer RL, Williams JB. User's guide for the structured clinical interview for DSM-IV axis I disorders, research version (SCID-I, version 2.0, February 1996 final version). Washington, DC: American Psychiatric Press; 1996.
  • 24
    Millon T, Davis R, Millon C. MCMI-III manual. 2nd ed. Minneapolis: NCS; 1997.
  • 25
    Rosenstiel AK, Keefe FJ. The use of coping strategies in chronic lower back pain patients: relationship to patient characteristics and current adjustment. Pain 1983; 17: 3344.
  • 26
    Swartzman LC, Gwadry FG, Shapiro AP, Teasell RW. The factor structure of the Coping Strategies Questionnaire. Pain 1994; 57: 3116.
  • 27
    Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol 1988; 54: 106370.
  • 28
    Hsu VM, Patella SJ, Sigal LH. “Chronic Lyme disease” as the incorrect diagnosis in patients with fibromyalgia. Arthritis Rheum 1993; 36: 1493500.
  • 29
    Fallon J, Bujak DI, Guardino S, Weinstein A. The Fibromyalgia Impact Questionnaire: a useful tool in evaluating patients with post–Lyme disease syndrome. Arthritis Care Res 1999; 12: 427.
  • 30
    Burckhardt CS, Clark SR, Bennett RM. The Fibromyalgia Impact Questionnaire: development and validation. J Rheumatol 1991; 18: 72833.
  • 31
    Bennett R. The Fibromyalgia Impact Questionnaire (FIQ): a review of its development, current version, operating characteristics and uses. Clin Exp Rheumatol 2005; 23(5 Suppl 39 ): S15462.
  • 32
    Somers RH. A new asymmetric measure of association for ordinal variables. Am Sociol Rev 1962; 27: 799811.
  • 33
    R Development Core Team. R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2007.
  • 34
    Centers for Disease Control. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995; 44: 5901.
  • 35
    US Department of Health and Human Services. Mental health: a report of the Surgeon General. Executive summary. Rockville (MD): US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Center for Mental Health Services, National Institutes of Health, National Institute of Mental Health; 1999.
  • 36
    Grant BF, Hasin DS, Stinson FS, Dawson DA, Chou SP, Ruan WJ, et al. Prevalence correlates and disability of personality disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. J Clin Psychiatry 2004; 65: 94858.
  • 37
    Lenzenweger MF, Lane MC, Loranger AW, Kessler RC. DSM-IV personality disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 62: 55364.
  • 38
    Fallon BA, Nields JA. Lyme disease: a neuropsychiatric illness. Am J Psychiatry 1994; 151: 157183.
  • 39
    Fallon BA, Nields JA, Parsons B, Liebowitz MR, Klein DF. Psychiatric manifestations of Lyme borreliosis. J Clin Psychiatry 1993; 54: 2638.
  • 40
    Steere AC. Musculoskeletal manifestations of Lyme disease [review]. Am J Med 1995; 98: 44S51S.
  • 41
    Lamberg L. Personality disorder a possibility in “problem” patients, specialists say. JAMA 2006; 296: 13412.
  • 42
    Walker EA, Katon WJ, Keegan D, Gardner G, Sullivan M. Predictors of physician frustration in the care of patients with rheumatological complaints. Gen Hosp Psychiatry 1997; 19: 31523.
  • 43
    Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, et al. EULAR evidence based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis. 2008; 67: 53641.
  • 44
    Woolfolk RL, Allen LA. Treating somatization: a cognitive-behavioral approach. New York: The Guilford Press; 2006.
  • 45
    Kroenke K. Efficacy of treatment for somatoform disorders: a review of randomized controlled trials. Psychosom Med 2007; 69: 8818.